Epistemonikos: El más rápido y confiable buscador de evidencia en salud

Revista » Alzheimer\'s & Dementia 2013;Conference: Alzheimer\'s Association International Conference 2013 Boston, MA United States. Conference Start: 20130713 Conference End: 20130718. Conference Publication:P655.

Año » 2013

Este artículo está incluido en 1 Revisión sistemática Revisiones sistemáticas (1 referencia)

Cargando información sobre las referencias

Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer\'s Disease as a function of disease severity: post hoc analysis from a randomized trial.

Autores » Tocco M , Hendrix S , Miller M , Pejovic V , Graham S

Revista » Annals of Neurology 2013;Conference: 138th Annual Meeting of the American Neurological Association, ANA 2013 New Orleans, LA United States. Conference Start: 20131013 Conference End: 20131015. Conference Publication:S92‐3

Año » 2013

Este artículo está incluido en 1 Revisión sistemática Revisiones sistemáticas (1 referencia)

Cargando información sobre las referencias

Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer\'s disease: Post hoc analysis from a randomized trial.

Autores » Tocco M , Hendrix S , Miller M , Pejovic V , Graham S.

Revista » Neurology

Año » 2013

Cargando información sobre las referencias

This article has no abstract

Estudios primarios incluidos en esta revisión sistemática

Efficacy of memantine ER on activities of daily living: a post hoc responder analysis from a randomized trial in patients with moderate‐to‐severe Alzheimer\'s disease

Maintenance of cognitive improvement treatment response with memantine and donepezil: post hoc analyses from a placebo controlled study in patients with moderate to severe Alzheimer\'s disease.

Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer\'s disease: subset analysis of a randomized clinical trial

Extended‐release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer\'s disease: an analysis of area under the curve

Cost‐effectiveness of memantine extended release for treatment of moderate‐to‐severe Alzheimer\'s disease in the United States. Alzheimer\'s & Dementia 2014;Conference: Alzheimer\'s Association International Conference 2014 Copenhagen Denmark.

Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer\'s disease: subset analysis of a randomized clinical trial

Cumulative benefits of extended‐release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer\'s disease: an area under the curve analysis

Clinical benefits of extended‐release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer\'s disease: Post hoc analysis from a randomized trial.

Benefits of extended‐release memantine in moderate‐to‐severe Alzheimer\'s Disease as a function of disease severity: post hoc analysis from a randomized trial.

Behavioral effects of extended‐release memantine (28 mg, once daily) across a wide range of disease severity in patients with moderate to severe alzheimer\'s disease: Post hoc analysis from a randomized trial.

Estudificar documentos